Kimelman & Baird, LLC Guardant Health, Inc. Transaction History
Kimelman & Baird, LLC
- $1.26 Trillion
- Q4 2024
A detailed history of Kimelman & Baird, LLC transactions in Guardant Health, Inc. stock. As of the latest transaction made, Kimelman & Baird, LLC holds 1,900 shares of GH stock, worth $91,428. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,900Holding current value
$91,428% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GH
# of Institutions
340Shares Held
119MCall Options Held
1.11MPut Options Held
2.07M-
Vanguard Group Inc Valley Forge, PA12.1MShares$580 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.2MShares$541 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.42MShares$309 Million8.64% of portfolio
-
Baillie Gifford & CO5.45MShares$262 Million0.13% of portfolio
-
Cadian Capital Management, LP New York, NY5.22MShares$251 Million9.25% of portfolio
About Guardant Health, Inc.
- Ticker GH
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 102,220,000
- Market Cap $4.92B
- Description
- Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...